Argenx (ARGX)
(Delayed Data from NSDQ)
$365.81 USD
-10.79 (-2.87%)
Updated May 17, 2024 04:00 PM ET
After-Market: $366.18 +0.37 (0.10%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
argenex SE [ARGX]
Reports for Purchase
Showing records 1 - 20 ( 278 total )
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Takeaways From AAN: ADHERE Data Presented at AAN Ahead of Vyvgart Hytrulo''s PDUFA in June
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Long Overlooked, Graves Disease Goes In Vogue With New Approaches
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Its Prime Time for FcRn with Vyvgart in the Spotlight
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
With the Present Bright With Vyvgart, argenx Begins to Highlight a Future Beyond
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Vyvgart Primed for Another Year of Dominance
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Equity Strategy - Wedbush Equity Strategy - Market Commentary
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Strong Sales Performance of Vyvgart; Eyes on Empasiprubart; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Another Setback Offers a Reminder That Drug Development is Hard; Price Target Down to $451
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D